Journal of Clinical Lipidology

Papers
(The H4-Index of Journal of Clinical Lipidology is 22. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
The National Lipid Association scientific statement on coronary artery calcium scoring to guide preventive strategies for ASCVD risk reduction123
Lipid measurements in the management of cardiovascular diseases: Practical recommendations a scientific statement from the national lipid association writing group81
NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient69
Saturated fats and cardiovascular health: Current evidence and controversies55
Impact of prior statin use on clinical outcomes in COVID-19 patients: data from tertiary referral hospitals during COVID-19 pandemic in Italy49
Ketogenic diets, not for everyone45
Long-term safety and efficacy of lomitapide in patients with homozygous familial hypercholesterolemia: Five-year data from the Lomitapide Observational Worldwide Evaluation Registry (LOWER)42
Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin/kexin type 9 inhibitor therapy: A randomized, controlled trial42
Pharmacokinetics and pharmacodynamics of inclisiran, a small interfering RNA therapy, in patients with hepatic impairment38
Guidance for the diagnosis and treatment of hypolipidemia disorders32
Assessment and management of statin-associated muscle symptoms (SAMS): A clinical perspective from the National Lipid Association31
Effects of bempedoic acid on CRP, IL-6, fibrinogen and lipoprotein(a) in patients with residual inflammatory risk: A secondary analysis of the CLEAR harmony trial30
A mechanism-based operational definition and classification of hypercholesterolemia28
Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association27
A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice26
HDL proteome remodeling associates with COVID-19 severity26
Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial25
Assessment of efficacy and safety of volanesorsen for treatment of metabolic complications in patients with familial partial lipodystrophy: Results of the BROADEN study25
Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials23
Association between antecedent statin use and severe disease outcomes in COVID-19: A retrospective study with propensity score matching23
Triglyceride-lowering and anti-inflammatory mechanisms of omega-3 polyunsaturated fatty acids for atherosclerotic cardiovascular risk reduction22
Nutrition interventions for adults with dyslipidemia: A Clinical Perspective from the National Lipid Association22
Association between statin use and cognitive function: A systematic review of randomized clinical trials and observational studies22
Prognostic impact of cascade screening for familial hypercholesterolemia on cardiovascular events22
Combined hyperlipidemia is genetically similar to isolated hypertriglyceridemia22
0.46807622909546